Abstract
This study was performed to investigate the effects of Lipoclin, a new lipid-lowering drug, on serum lipoproteins, apoproteins (A-I, A-II) and LCAT activity in 14 hyperlipidemic patients (Type IIa, IIb). The patients were administered 600mg Lipoclin daily for twelve weeks and the following results were obtained.
(1) Lipoclin produced a significant redution of total cholesterol, VLDL-cholesterol, LDL-cholesterol and triglicerides (VLDL-TG LDL-TG), but increased in HDL-cholesterol significantly (p<0.01).
(2) In high density lipoprotein subfractions (HDL2 and HDL3), Lipoclin increased HDL2-cholesterol significantly (p<0.001) whereas the HDL3-cholesterol remained unchanged.
(3) Lipoclin treatment also caused significant increases in both of the plasma apoprotein A-I (p<0.01) and LCAT activity (p<0.01) but did not influence the level of apoprotein A-II.
